TREA

79244477 - CURADIGM

Follow

Information

  • Trademark
  • 79244477
  • Serial Number
    79244477
  • Registration Number
    5796583
  • Filing Date
    August 01, 2018
    5 years ago
  • Registration Date
    July 09, 2019
    4 years ago
  • Transaction Date
    February 28, 2020
    4 years ago
  • Status Date
    July 09, 2019
    4 years ago
  • Published for Opposition Date
    April 23, 2019
    5 years ago
  • Location Date
    July 09, 2019
    4 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    BROWN, TRICIA LYNN
  • Law Office Assigned Location Code
    N30
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
CURADIGM
Case File Statements
  • CC0000: Color is not claimed as a feature of the mark.
  • GS0051: Products for medical use especially for metabolic pathways, namely, enzyme substrates and enzyme inhibitors; products for medical use especially for the diagnosis and treatment of tumors, namely, diagnostic preparation for medical purposes for the diagnosis of tumors and therapeutic pharmaceutical preparations for medical purposes for the treatment of tumors and rare hepatic diseases; preparations for medical use especially for modifying the bioavailability of therapeutic agents, namely, lipidic and polymeric formulation for drug delivery in the nature of drug delivery agents in the form of nanoparticles, nanovesicles, particles, vesicles, dissolvable films, coatings for tablets and hydrogels that facilitate the delivery of pharmaceutical preparations; preparations for medical use especially for modifying liver functions, namely, pharmaceutical preparations for the treatment of liver diseases and disorders and pharmaceutical preparations to alter hepatic metabolization pathways; preparations for medical use for modifying the functions of the reticuloendothelial system, namely, pharmaceutical preparations for the treatment of reticuloendothelial system diseases and disorders and pharmaceutical preparations to alter reticuloendothelial system endocytosis pathways; preparations made with nanomaterials for the delivery of therapeutic agents, namely, drug delivery agents in the form of enterally, parenterally in the nature of intravenous, or topically administered nanomaterials that facilitate the delivery of pharmaceutical preparations; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use for the treatment of cancer, central nervous system disorders, cardiological, immunological, gastrointestinal, metabolic and infection diseases; enzymes for medical use; enzyme preparations for medical use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infection diseases; diagnostic products for medical use, namely, diagnostic preparations for medical purposes; drugs for medical use, namely, medical preparations for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infectious diseases; medicines for human medicine, namely, medical preparations for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infectious diseases; tonics medicines, namely, medical herbal preparations; antibiotics; antiseptics; chemico-pharmaceutical products for the treatment of the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infection diseases; pharmaceutical products, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic substances for medical use, namely, dietetic foods adapted for medical purposes; remedies for human medicine, namely, natural remedy preparations for the treatment of gastrointestinal conditions, hormonal and chemical imbalances, and sleep disorders
  • GS0101: Surgical and medical apparatus and instruments especially for the diagnosis and treatment of tumors; Surgical and medical apparatus and instruments especially for monitoring and modifying metabolic functions; Apparatus for modifying the functions of the reticuloendothelial system, namely, medical apparatus and instruments for use in endovascular and cardiovascular procedures; Apparatus for modulating liver functions, namely, medical apparatus and instruments for use in measuring, quantifying and assessing liver health and oxygenation and perfusion apparatus in the nature of perfusion pumps for liver transplantation; Apparatus for the delivery of therapeutic or diagnostic agents, namely, medical apparatus and units for dosage, measuring and monitoring, in the nature of drug delivery devices and systems, and organ oxygenation and perfusion apparatus in the nature of perfusion pumps; Apparatus for modulating hepatic blood flow, namely, organ perfusion apparatus in the nature of perfusion pumps; Testing apparatus for medical use in the nature of medical diagnostic apparatus for testing cancer calls, DNA, organ oxygenation and blood sugar levels; Diagnostic apparatus for medical use for testing cancer calls, DNA, organ oxygenation and blood sugar levels
  • GS0421: Scientific and technological services, namely, research and design especially in the field of nanomedicine, in the nature of nanotechnology applied to medicine; Biological research services; Bacteriological research services; Evaluations, estimates and research in scientific and technological fields provided by engineers and researchers, namely, conducting early evaluations in the field of new pharmaceuticals; Design and development of new products for third parties in the field of pharmaceutical preparations and diagnostic devices design; Technical research in the field of pharmaceutical project studies; Industrial analysis and research services, namely, biomedical research services; Chemical analysis; Chemical research; Chemistry services, namely, chemistry consultation; Surveying, namely, engineering work; Research and development of new products for others; Technical research in the field of pharmaceutical studies; Biological research, namely, radiobiology research, biological, pharmacokinetic, pharmacodynamic and immunological evaluation and toxicological evaluation; Medical research, namely, research in nanoscience and nanotechnology, especially applied to medicine
  • GS0441: Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Case File Event Statements
  • 2/27/2020 - 4 years ago
    33 - CHANGE OF OWNER RECEIVED FROM IB Type: CHLD
  • 11/15/2019 - 4 years ago
    32 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 10/29/2019 - 4 years ago
    31 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 10/29/2019 - 4 years ago
    30 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 10/9/2019 - 4 years ago
    29 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 7/9/2019 - 4 years ago
    28 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 5/3/2019 - 5 years ago
    27 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 4/23/2019 - 5 years ago
    26 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/17/2019 - 5 years ago
    25 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 4/17/2019 - 5 years ago
    24 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 4/3/2019 - 5 years ago
    23 - NOTICE OF PUBLICATION Type: NPUB
  • 3/15/2019 - 5 years ago
    22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 3/15/2019 - 5 years ago
    21 - EXAMINERS AMENDMENT MAILED Type: CNEA
  • 3/14/2019 - 5 years ago
    20 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 3/14/2019 - 5 years ago
    19 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 3/8/2019 - 5 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/7/2019 - 5 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/7/2019 - 5 years ago
    16 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 3/4/2019 - 5 years ago
    15 - FINAL REFUSAL MAILED Type: CNFR
  • 3/1/2019 - 5 years ago
    14 - FINAL REFUSAL WRITTEN Type: CNFR
  • 2/8/2019 - 5 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/8/2019 - 5 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/7/2019 - 5 years ago
    11 - ASSIGNED TO LIE Type: ALIE
  • 2/3/2019 - 5 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/21/2018 - 5 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 12/4/2018 - 5 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 12/4/2018 - 5 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 11/19/2018 - 5 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 11/18/2018 - 5 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/18/2018 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/13/2018 - 5 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 11/7/2018 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 11/1/2018 - 5 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR